Thrombocytopenia is more severe in patients with chronic hepatitis C than in patients with nonalcoholic fatty liver disease

Mawatari, Hironori; Yoneda, Masato; Kohno, Hiroyuki; Maeda, Shin; Nakajima, Atsushi; Saito, Satoru

doi:10.1007/s00535-012-0556-5

Cited by 14 publications

(16 citation statements)

References 7 publications

(7 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In our study, hemoglobin level was significantly reduced than the control group, but various literature mentioned that high HGB significantly added to the risk of NAFLD [36]. Similarly, the platelet count is clinically important to predict the status of hepatic fibrosis in patients with chronic hepatic diseases [37]. We have reported significantly lower platelet count in patients, which is consistent with the study done by Suzuki et al [33].…”

Section: Discussion:-supporting

confidence: 91%

Biochemical and Hematological Profile of Fatty Liver Patients From Western Nepal.

Tamrakar¹,

Nagila²,

Abdalhabib³

et al. 2017

IJAR

View full text Add to dashboard Cite

Section: Discussion:-supporting

confidence: 91%

Biochemical and Hematological Profile of Fatty Liver Patients From Western Nepal.

Tamrakar¹,

Nagila²,

Abdalhabib³

et al. 2017

IJAR

View full text Add to dashboard Cite

“…Thrombocytopenia is a common finding in advanced stages of all chronic hepatic diseases, and platelet count is clinically important to predict status of hepatic fibrosis in patients with chronic hepatic diseases[66]. In NAFLD, platelets are important in terms of absolute number as well as volume.…”

Section: Inflammatory Markersmentioning

confidence: 99%

Nonalcoholic fatty liver disease: Diagnostic biomarkers

Hadizadeh

Faghihimani

Adibi

2017

WJGP

132

View full text Add to dashboard Cite

Nonalcoholic fatty liver disease is a common medical condition worldwide and its prevalence has increased notably in the past few years due to the increases in prevalence of obesity and metabolic syndrome. However, diagnosis of this disease is still a matter of debate because of disease variations and pathophysiologic alterations. Specific single markers have gained considerable attention recently, among them markers related to hepatic pathophysiology, inflammation, adipocytokines and so forth. But, it seems that no single marker is sufficient for diagnosis and staging of the disease, and applying a panel including different types of tests may be more useful.

show abstract

“…Although there are platelet count data for NAFLD and chronic liver disease due to hepatitis C virus (CLD-HCV), they were gathered at different institutes and could not be directly compared ( 7 - 9 ). Mawatari et al reported on the relationship between liver stiffness (as assessed by transient elastography ) and the platelet count in CLD-HCV and NAFLD ( 12 ). However, they did not investigate the relationship between the histological findings of liver fibrosis and the platelet count in the two diseases.…”

Section: Introductionmentioning

confidence: 99%

The Clinical Difference in the Platelet Counts between Liver Cirrhosis with Nonalcoholic Fatty Liver Disease and Hepatitis C Virus

et al. 2018

View full text Add to dashboard Cite

Objective The rate of platelet count reduction appears to differ among different liver diseases. In the present study, we investigated the difference in the platelet counts of patients with nonalcoholic fatty liver disease (NAFLD) and those with chronic liver disease due to hepatitis C virus (CLD-HCV). Methods The study population included 620 patients with NAFLD and 405 patients with CLD-HCV, all of whom were diagnosed by liver biopsy. The relationships between the grade of fibrosis and the platelet count in the two diseases were compared. The optimal cut-off value for the diagnosis of liver cirrhosis (LC) was measured. The relationships between the platelet count and anti-platelet antibodies, the serum thrombopoietin level, the grade of splenomegaly and liver stiffness were also investigated in both LC groups. Results In NAFLD patients, the platelet count was significantly higher at each grade of fibrosis in comparison to CLD-HCV. The optimal cut-off value for the diagnosis of LC was 16.0×104/μL [sensitivity, 86.7%; specificity, 87.6%; area under the curve (AUC), 0.930] in NAFLD and 12.7×104/μL (sensitivity, 57.8%; specificity, 88.2%; AUC, 0.863) in CLD-HCV. No anti-platelet antibodies were detected in patients with either type of LC. The serum thrombopoietin levels, the distribution of splenomegaly grades, and liver stiffness did not differ between the two LC groups to a statistically significant extent. As the splenomegaly grade increased, the platelet count decreased. Conclusion The optimal cut-off values for diagnosing LC differed between the two diseases and should be determined separately. The reason for the difference in platelet reduction is still unclear, and requires further investigation.

show abstract

Thrombocytopenia is more severe in patients with chronic hepatitis C than in patients with nonalcoholic fatty liver disease

Cited by 14 publications

References 7 publications

Biochemical and Hematological Profile of Fatty Liver Patients From Western Nepal.

Biochemical and Hematological Profile of Fatty Liver Patients From Western Nepal.

Nonalcoholic fatty liver disease: Diagnostic biomarkers

The Clinical Difference in the Platelet Counts between Liver Cirrhosis with Nonalcoholic Fatty Liver Disease and Hepatitis C Virus

Contact Info

Product

Resources

About